Nielsen Jakob, Kwon Tae-Hwan, Frøkiaer Jørgen, Knepper Mark A, Nielsen Søren
The Water and Salt Research Center, Institute of Anatomy (Bldg. 233 Univ. of Aarhus, DK-8000 Aarhus, Denmark.
Am J Physiol Renal Physiol. 2006 May;290(5):F1222-33. doi: 10.1152/ajprenal.00321.2005. Epub 2005 Dec 6.
Lithium-induced nephrogenic diabetes insipidus (Li-NDI) is associated with increased urinary sodium excretion and decreased responsiveness to aldosterone and vasopressin. Dysregulation of the epithelial sodium channel (ENaC) is thought to play an important role in renal sodium wasting. The effect of 7-day aldosterone and spironolactone treatment on regulation of ENaC in rat kidney cortex was investigated in rats with 3 wk of Li-NDI. Aldosterone treatment of rats with Li-NDI decreased fractional excretion of sodium (0.83 +/- 0.02), whereas spironolactone did not change fractional excretion of sodium (1.10 +/- 0.11) compared with rats treated with lithium alone (1.11 +/- 0.05). Plasma lithium concentration was decreased by aldosterone (0.31 +/- 0.03 mmol/l) but unchanged with spironolactone (0.84 +/- 0.18 mmol/l) compared with rats treated with lithium alone (0.54 +/- 0.04 mmol/l). Immunoblotting showed increased protein expression of alpha-ENaC, the 70-kDa form of gamma-ENaC, and the Na-Cl cotransporter (NCC) in kidney cortex in aldosterone-treated rats, whereas spironolactone decreased alpha-ENaC and NCC compared with control rats treated with lithium alone. Immunohistochemistry confirmed increased expression of alpha-ENaC in the late distal convoluted tubule and connecting tubule and also revealed increased apical targeting of all three ENaC subunits (alpha, beta, and gamma) in aldosterone-treated rats compared with rats treated with lithium alone. Aldosterone did not, however, affect alpha-ENaC expression in the cortical collecting duct (CCD), which showed weak and dispersed labeling similar to that in rats treated with lithium alone. Spironolactone did not affect ENaC targeting compared with rats treated with lithium alone. This study shows a segment specific lack of aldosterone-mediated alpha-ENaC regulation in the CCD affecting both alpha-ENaC protein expression and trafficking, which may explain the increased sodium wasting associated with chronic lithium treatment.
锂诱导的肾性尿崩症(Li-NDI)与尿钠排泄增加以及对醛固酮和血管加压素的反应性降低有关。上皮钠通道(ENaC)的失调被认为在肾钠流失中起重要作用。在患有3周Li-NDI的大鼠中,研究了7天醛固酮和螺内酯治疗对大鼠肾皮质中ENaC调节的影响。与单独用锂治疗的大鼠(1.11±0.05)相比,用醛固酮治疗Li-NDI大鼠可降低钠分数排泄(0.83±0.02),而螺内酯未改变钠分数排泄(1.10±0.11)。与单独用锂治疗的大鼠(0.54±0.04 mmol/l)相比,醛固酮使血浆锂浓度降低(0.31±0.03 mmol/l),但螺内酯使其未改变(0.84±0.18 mmol/l)。免疫印迹显示,醛固酮治疗的大鼠肾皮质中α-ENaC、70 kDa形式的γ-ENaC和钠氯共转运体(NCC)的蛋白表达增加,而与单独用锂治疗的对照大鼠相比,螺内酯降低了α-ENaC和NCC。免疫组织化学证实,与单独用锂治疗的大鼠相比,醛固酮治疗的大鼠远端曲小管后期和连接小管中α-ENaC的表达增加,并且还显示所有三个ENaC亚基(α、β和γ)的顶端靶向增加。然而,醛固酮并未影响皮质集合管(CCD)中α-ENaC的表达,其显示出与单独用锂治疗的大鼠相似的弱且分散的标记。与单独用锂治疗的大鼠相比,螺内酯不影响ENaC靶向。这项研究表明,CCD中醛固酮介导的α-ENaC调节存在节段特异性缺失,影响α-ENaC蛋白表达和转运,这可能解释了与慢性锂治疗相关的钠流失增加。